АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология

Supporting Information

Прочитайте:
  1. Ex. 9 Read the information and act out your own dialog.
  2. General requirements to articles and information about the author
  3. Information and didactic part
  4. INFORMATION GUIDE
  5. Study the information.
  6. Text A. Information Age: For and Against
  7. І Read the information about letters.

 

S1 Data. The French Realistic Virtual Population database.

It contains the data of every virtual individual (rows) characterised by 16 covariates (columns).

doi:10.1371/journal.pone.0140793.s001

(ZIP)

S2 Data. A description of the covariates included in S1 Data.

doi:10.1371/journal.pone.0140793.s002

(TXT)

Acknowledgments

The authors would like to thank NovaDiscovery for sharing the simulation platform, without which this study would not have been feasible.

Author Contributions

Conceived and designed the experiments: IM FG. Performed the experiments: IM FG. Analyzed the data: IM FG JPB PN. Contributed reagents/materials/analysis tools: FG PN IM JPB. Wrote the paper: IM FG.

References

  1. 1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33: 1635–1701. doi: 10.1093/eurheartj/ehs092. pmid:22555213
  1. 2. Marchant I, Nony P, Cucherat M, Boissel JP, Thomas SR, Bejan-Angoulvant T, et al. (2011) The global risk approach should be better applied in French hypertensive patients: a comparison between simulation and observation studies. PLoS One 6: e17508. doi: 10.1371/journal.pone.0017508. pmid:21408615
  2. 3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601–1610. pmid:12964575 doi: 10.1097/00149831-200312001-00001
  3. 4. Rose G (1981) Strategy of prevention: lessons from cardiovascular disease. British medical journal (Clinical research ed) 282: 1847–1851. doi: 10.1136/bmj.282.6279.1847
  4. 5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462–1536. pmid:17562668 doi: 10.1097/hjh.0b013e3281fc975a
  5. 6. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28: 2375–2414. pmid:17726041 doi: 10.1093/eurheartj/ehm316
  6. 7. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159–2219. doi: 10.1093/eurheartj/eht151. pmid:23771844
  7. 8. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P (2007) Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. Bmj 335: 136. pmid:17615182 doi: 10.1136/bmj.39261.471806.55
  8. 9. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ (2011) Discounting and decision making in the economic evaluation of health-care technologies. Health Econ 20: 2–15. doi: 10.1002/hec.1612. pmid:21154521
  9. 10. Sozou PD (2009) Individual and social discounting in a viscous population. Proc Biol Sci 276: 2955–2962. doi: 10.1098/rspb.2009.0401. pmid:19474046
  10. 11. Nord E (2011) Discounting future health benefits: the poverty of consistency arguments. Health Econ 20: 16–26. doi: 10.1002/hec.1687. pmid:21154522
  11. 12. Earnshaw J, Lewis G (2008) NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective. Pharmacoeconomics 26: 725–727. pmid:18767892 doi: 10.2165/00019053-200826090-00002
  12. 13. Torgerson DJ, Raftery J (1999) Economic notes. Discounting. Bmj 319: 914–915. pmid:10506056 doi: 10.1136/bmj.319.7214.914
  13. 14. Liew SM, Jackson R, Mant D, Glasziou P (2012) Should identical CVD risks in young and old patients be managed identically? Results from two models. BMJ Open 2: e000728. doi: 10.1136/bmjopen-2011-000728. pmid:22382122
  14. 15. Marchant I, Boissel JP, Kassai B, Bejan T, Massol J, Vidal C, et al. (2009) SCORE should be preferred to Framingham to predict cardiovascular death in French population. Eur J Cardiovasc Prev Rehabil 16: 609–615. doi: 10.1097/HJR.0b013e32832da006. pmid:20054289
  15. 16. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24: 987–1003. pmid:12788299 doi: 10.1016/s0195-668x(03)00114-3
  16. 17. R Development Core Team (2011) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.
  17. 18. Boissel JP, Kahoul R, Amsallem E, Gueyffier F, Haugh M, Boissel FH (2011) Towards personalized medicine: exploring the consequences of the effect model-based approach. Personalized Medicine 8: 581–586. doi: 10.2217/pme.11.54
  18. 19. Gueyffier F, Froment A, Gouton M (1996) New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens 10: 1–8. pmid:8642184
  19. 20. Capewell S, Hayes DK, Ford ES, Critchley JA, Croft JB, Greenlund KJ, et al. (2009) Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000. Am J Epidemiol 170: 229–236. doi: 10.1093/aje/kwp150. pmid:19541856
  20. 21. (2003) Techniques to measure the impact of mortality: years of potential life lost. Epidemiol Bull 24: 1–4.
  21. 22. (2010) Insee—Population—Évolution de l’espérance de vie à divers âges.
  22. 23. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F (2007) Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ 16: 307–317. pmid:17006970 doi: 10.1002/hec.1168
  23. 24. WHO Definition of an older or elderly person. EWorld Health Organization.
  24. 25. Erhardt LR, Gotto A Jr. (2006) The evolution of European guidelines: changing the management of cholesterol levels. Atherosclerosis 185: 12–20. pmid:16309687 doi: 10.1016/j.atherosclerosis.2005.10.001
  25. 26. Spiegelhalter DJ, Gore SM, Fitzpatrick R, Fletcher AE, Jones DR, Cox DR (1992) Quality of life measures in health care. III: Resource allocation. Bmj 305: 1205–1209. pmid:1304741 doi: 10.1136/bmj.305.6863.1205
  26. 27. Kahn R, Robertson RM, Smith R, Eddy D (2008) The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care 31: 1686–1696. doi: 10.2337/dc08-9022. pmid:18663233
  27. 28. Thomopoulos C, Parati G, Zanchetti A (2014) Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk—overview and meta-analyses of randomized trials. J Hypertens 32: 2305–2314. doi: 10.1097/HJH.0000000000000380. pmid:25259548
  28. 29. Sundstrom J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D, et al. (2014) Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384: 591–598. doi: 10.1016/S0140-6736(14)61212-5. pmid:25131978
  29. 30. Granstrom O, Levin LA, Henriksson M (2012) Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension. Clinicoecon Outcomes Res 4: 313–322. doi: 10.2147/CEOR.S35824. pmid:23144565
  30. 31. Goldman DP, Zheng Y, Girosi F, Michaud PC, Olshansky SJ, Cutler D, et al. (2009) The benefits of risk factor prevention in Americans aged 51 years and older. Am J Public Health 99: 2096–2101. doi: 10.2105/AJPH.2009.172627. pmid:19762651
  31. 32. Athanasakis K, Souliotis K, Tountas Y, Kyriopoulos J, Hatzakis A (2012) A cost-utility analysis of hypertension treatment in Greece: assessing the impact of age, sex and smoking status, on outcomes. J Hypertens 30: 227–234. doi: 10.1097/HJH.0b013e32834d9f18. pmid:22157591
  32. 33. Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Gomez-Perez FJ, Aguilar-Salinas CA (2010) UKPDS Risk Engine, decode and diabetes PHD models for the estimation of cardiovascular risk in patients with diabetes. Curr Diabetes Rev 6: 1–8. pmid:20034373 doi: 10.2174/157339910790442646
  33. 34. Coleman R, Stevens R, Holman R (2012) Updated UKPDS Risk Engine that Estimates Primary and Secondary Cardiovascular Disease Risk in People With Recently-Diagnosed or Established Type 2 Diabetes. Diabetes 61: A103.
  34. 35. Thomsen TF, McGee D, Davidsen M, Jorgensen T (2002) A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 31: 817–822. pmid:12177028 doi: 10.1093/ije/31.4.817
  35. 36. Kengne AP, Patel A, Colagiuri S, Heller S, Hamet P, Marre M, et al. (2010) The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 53: 821–831. doi: 10.1007/s00125-010-1681-4. pmid:20157695
  36. 37. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD (2005) Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med 22: 554–562. pmid:15842509 doi: 10.1111/j.1464-5491.2005.01494.x
  37. 38. van der Heijden AAWA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM (2009) Prediction of Coronary Heart Disease Risk in a General, Pre-Diabetic, and Diabetic Population During 10 Years of Follow-up: Accuracy of the Framingham, SCORE, and UKPDS Risk Functions The Hoorn Study. Diabetes Care 32: 2094–2098. doi: 10.2337/dc09-0745. pmid:19875606
  38. 39. Hense HW, Schulte H, Lowel H, Assmann G, Keil U (2003) Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 24: 937–945. pmid:12714025 doi: 10.1016/s0195-668x(03)00081-2
  39. 40. Coleman RL, Stevens RJ, Retnakaran R, Holman RR (2007) Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 30: 1292–1293. pmid:17290036 doi: 10.2337/dc06-1358
  40. 41. Diao D, Wright JM, Cundiff DK, Gueyffier F (2012) Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev 8: CD006742. doi: 10.1002/14651858.CD006742.pub2. pmid:22895954

 

Дата добавления: 2015-11-26 | Просмотры: 612 | Нарушение авторских прав

При использовании материала ссылка на сайт medlec.org обязательна! (0.003 сек.)